The prospect of Computer-Assisted Instant Monitoring drug Administration is discussed based on 8-year experience of exprimental and clinical research. The CAIMA system is composed of a negative feed-back closed loop, ...The prospect of Computer-Assisted Instant Monitoring drug Administration is discussed based on 8-year experience of exprimental and clinical research. The CAIMA system is composed of a negative feed-back closed loop, with the living organism as a link within the loop. Transducers are of vital importance, and need improvement as to sensitivity and specificity in order to transform the relevant biological phenomena into electrical signal. The range of the Controlled levels should be known in advance. Drugs of short duration, with rapid onset should be chosen for first trials. Slowly acting drugs, with long half lives need special programs with multi-criteria. The total dose, the therapeutic ranges and other relevant doses should be calculated by CAIMA. The possiblility of presetting the reaction level is the most salient feature of CAIMA, which would revolutionize the mode of drug administration. The author’s opinion is that: CAIMA is ideal for phase Ⅰof clinical trials to find the tolerated dose ranges while the drug-sparing property would make a poison most useful in critical situations. The knowledge on CAIMA is scanty and need strong propagation, while the intimate collaboration of clinicians, computer-men, pharmacologists, mathematicians and marketting-people is badly needed.展开更多
文摘The prospect of Computer-Assisted Instant Monitoring drug Administration is discussed based on 8-year experience of exprimental and clinical research. The CAIMA system is composed of a negative feed-back closed loop, with the living organism as a link within the loop. Transducers are of vital importance, and need improvement as to sensitivity and specificity in order to transform the relevant biological phenomena into electrical signal. The range of the Controlled levels should be known in advance. Drugs of short duration, with rapid onset should be chosen for first trials. Slowly acting drugs, with long half lives need special programs with multi-criteria. The total dose, the therapeutic ranges and other relevant doses should be calculated by CAIMA. The possiblility of presetting the reaction level is the most salient feature of CAIMA, which would revolutionize the mode of drug administration. The author’s opinion is that: CAIMA is ideal for phase Ⅰof clinical trials to find the tolerated dose ranges while the drug-sparing property would make a poison most useful in critical situations. The knowledge on CAIMA is scanty and need strong propagation, while the intimate collaboration of clinicians, computer-men, pharmacologists, mathematicians and marketting-people is badly needed.
